Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 8
2009 5
2010 7
2011 7
2012 7
2013 5
2014 2
2015 3
2016 5
2017 7
2018 5
2019 17
2020 15
2021 12
2022 5
2023 5
2024 16

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

105 results

Results by year

Filters applied: . Clear all
Page 1
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer.
Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, Hasegawa K, Hotta K, Ishida H, Ishiguro M, Ishihara S, Kanemitsu Y, Kinugasa Y, Murofushi K, Nakajima TE, Oka S, Tanaka T, Taniguchi H, Tsuji A, Uehara K, Ueno H, Yamanaka T, Yamazaki K, Yoshida M, Yoshino T, Itabashi M, Sakamaki K, Sano K, Shimada Y, Tanaka S, Uetake H, Yamaguchi S, Yamaguchi N, Kobayashi H, Matsuda K, Kotake K, Sugihara K; Japanese Society for Cancer of the Colon and Rectum. Hashiguchi Y, et al. Among authors: nakajima te. Int J Clin Oncol. 2020 Jan;25(1):1-42. doi: 10.1007/s10147-019-01485-z. Epub 2019 Jun 15. Int J Clin Oncol. 2020. PMID: 31203527 Free PMC article.
2023 Japan Society of clinical oncology clinical practice guidelines update for antiemesis.
Iihara H, Abe M, Wada M, Iino K, Akechi T, Imamura CK, Okuyama A, Ozawa K, Kim YI, Sasaki H, Satomi E, Takeda M, Tanaka R, Nakajima TE, Nakamura N, Nishimura J, Noda M, Hayashi K, Higashi T, Boku N, Matsumoto K, Matsumoto Y, Okita K, Yamamoto N, Aogi K. Iihara H, et al. Among authors: nakajima te. Int J Clin Oncol. 2024 Jul;29(7):873-888. doi: 10.1007/s10147-024-02535-x. Epub 2024 May 16. Int J Clin Oncol. 2024. PMID: 38753042 Free PMC article.
Dexamethasone-sparing on days 2-4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial).
Minatogawa H, Izawa N, Shimomura K, Arioka H, Iihara H, Sugawara M, Morita H, Mochizuki A, Nawata S, Mishima K, Tsuboya A, Miyaji T, Honda K, Yokomizo A, Hashimoto N, Yanagihara T, Endo J, Kawaguchi T, Furuya N, Sone Y, Inada Y, Ohno Y, Katada C, Hida N, Akiyama K, Ichikura D, Konomatsu A, Ogura T, Yamaguchi T, Nakajima TE. Minatogawa H, et al. Among authors: nakajima te. Br J Cancer. 2024 Feb;130(2):224-232. doi: 10.1038/s41416-023-02493-7. Epub 2023 Nov 16. Br J Cancer. 2024. PMID: 37973958 Free PMC article. Clinical Trial.
Reply to L. Celio et al.
Minatogawa H, Izawa N, Nakajima TE. Minatogawa H, et al. Among authors: nakajima te. Br J Cancer. 2024 Jun;130(12):1887-1888. doi: 10.1038/s41416-024-02708-5. Epub 2024 May 15. Br J Cancer. 2024. PMID: 38750116 No abstract available.
Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer.
Sunakawa Y, Kuboki Y, Watanabe J, Terazawa T, Kawakami H, Yokota M, Nakamura M, Kotaka M, Sugimoto N, Ojima H, Oki E, Kajiwara T, Yamamoto Y, Tsuji Y, Denda T, Tamura T, Ishihara S, Taniguchi H, Nakajima TE, Morita S, Shirao K, Takenaka N, Ozawa D, Yoshino T. Sunakawa Y, et al. Among authors: nakajima te. Target Oncol. 2024 Jan;19(1):59-69. doi: 10.1007/s11523-023-01027-8. Epub 2024 Jan 9. Target Oncol. 2024. PMID: 38194163 Free PMC article. Clinical Trial.
Reply to L. Celio et al.
Ito Y, Tsuda T, Sakamaki K, Nakajima TE. Ito Y, et al. Among authors: nakajima te. J Clin Oncol. 2018 Sep 10;36(26):2742-2743. doi: 10.1200/JCO.2018.79.1772. Epub 2018 May 25. J Clin Oncol. 2018. PMID: 29799772 No abstract available.
Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial.
Kuboki Y, Terazawa T, Masuishi T, Nakamura M, Watanabe J, Ojima H, Makiyama A, Kotaka M, Hara H, Kagawa Y, Sugimoto N, Kawakami H, Takashima A, Kajiwara T, Oki E, Sunakawa Y, Ishihara S, Taniguchi H, Nakajima TE, Morita S, Shirao K, Takenaka N, Ozawa D, Yoshino T. Kuboki Y, et al. Among authors: nakajima te. Br J Cancer. 2023 May;128(10):1897-1905. doi: 10.1038/s41416-023-02212-2. Epub 2023 Mar 4. Br J Cancer. 2023. PMID: 36871043 Free PMC article. Clinical Trial.
Non-pharmacological treatments for anticipatory nausea and vomiting during chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023.
Kobayashi M, Kako J, Iba A, Okuyama A, Ozawa K, Abe M, Wada M, Akechi T, Iihara H, Imamura CK, Kim YI, Sasaki H, Satomi E, Takeda M, Tanaka R, Nakajima TE, Nakamura N, Nishimura J, Noda M, Hayashi K, Higashi T, Boku N, Matsumoto K, Matsumoto Y, Okita K, Yamamoto N, Aogi K, Iino K. Kobayashi M, et al. Among authors: nakajima te. Int J Clin Oncol. 2024 Jul;29(7):889-898. doi: 10.1007/s10147-024-02536-w. Epub 2024 May 9. Int J Clin Oncol. 2024. PMID: 38722486
Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild-type metastatic colorectal cancer: A phase II trial (HYBRID).
Arai H, Tsuda T, Sunakawa Y, Shimokawa M, Akiyoshi K, Tokunaga S, Shoji H, Kunieda K, Kotaka M, Matsumoto T, Nagata Y, Mizukami T, Mizuki F, Danenberg KD, Boku N, Nakajima TE. Arai H, et al. Among authors: nakajima te. Cancer Med. 2024 Apr;13(7):e7107. doi: 10.1002/cam4.7107. Cancer Med. 2024. PMID: 38591098 Free PMC article. Clinical Trial.
105 results